What is New with the β 2 -Agonists: Issues in the Management of Asthma

Abstract

Spanish

French

OBJECTIVE:

To review the more recent literature addressing the issue of whether β₂-agonists can worsen asthma and/or increase the risk of severe exacerbations and death from asthma.

DATA SOURCES:

PubMed was searched (2001–December 2004), along with the Food and Drug Administration and Cochrane Library Web sites. In addition, the bibliographies of recent reviews of the subject were assessed.

STUDY SELECTION AND DATA EXTRACTION:

Randomized clinical trials, retrospective and prospective cohort studies, and meta-analyses published in the past 3 years were reviewed. Studies assessing the potential for β₂-agonists to worsen outcomes in asthma as well as long-term studies assessing asthma outcomes that included an arm with regular administration of short- or long-acting inhaled β₂-agonists (LABAs) were selected. Worsening asthma was defined as a decline in lung function, an increase in bronchial hyperresponsiveness, exacerbations, or death. Studies older than 3 years selected from the bibliographies of the primary articles that addressed background perspective were also included where appropriate.

DATA SYNTHESIS:

The studies fell into 3 primary categories with some overlap: those assessing toxicity of the S-enantiomer of albuterol, those evaluating the risk of specific genotypes regarding worsening asthma, and those assessing asthma outcomes with LABA therapy.

CONCLUSIONS:

The current data on the use of β₂-agonists continue to support the national and international guidelines for the treatment of asthma. That is, short-acting inhaled β₂-agonists should only be used as needed for symptoms and prevention of exercise-induced bronchospasm, and LABAs should only be used regularly as adjunctive therapy with inhaled corticosteroids in patients whose asthma is not controlled with low to medium doses of the inhaled corticosteroid.

Keywords

albuterol asthma formoterol levalbuterol salmeterol

Get full access to this article

View all access options for this article.

References

National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education Prevention Program. Expert Panel report 2: guidelines for the diagnosis and management of asthma. Publication No. 97–4051. Bethesda, MD: National Institutes of Health, 1997.

National Institutes of Health: National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention revised (2002). NHLBI/WHO Workshop Report. Publication No. 02–3659. Bethesda, MD: 2002.

National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel report: Guidelines for the diagnosis and management of asthma update on selected topics—2002. J Allergy Clin Immunol 2002; 110 (5 suppl): S141–219.

Agency for Healthcare Research and Quality. Management of chronic asthma. Evidence report/technology assessment, Number 44. AHRQ Publication No. 01-E044, 2001. www.ahrq.gov (accessed 2005 Jan 21).

Israel

Drazen

Liggett

Boushey

Cherniack

Chinchilli

. The effect of polymorphisms of the β₂ adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75–80.

Taylor

Drazen

Herbison

Yandava

Hancox

Town

. Asthma exacerbations during long term β agonist use: Influence of β₂ adrenoceptor polymorphism. Thorax 2000; 55: 762–7.

GlaxoSmithKline. The salmeterol multicenter asthma research trial (SMART). Data on file. GlaxoSmithKline (SLGA5011).

McFadden

Jr . Perspectives in β₂-agonist therapy: Vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995; 95: 641–51.

McFadden

Jr . Acute severe asthma. Am J Respir Crit Care Med 2003; 168: 740–59.

10.

Burggraaf

Westendorp

in't Veen

Schoemaker

Sterk

Cohen

. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56: 567–9.

11.

Curtis

Every

McDonell

Fihn

. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846–51.

12.

Suissa

Assimes

Ernst

. Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58: 43–6.

13.

Jenne

Kelly

. β₂ Agonists. In: Murphy

Kelly

, eds. Pediatric asthma (lung biology in health and disease series/126). New York: Marcel Dekker, 1999: 279–326.

14.

Lipworth

Aziz

. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; 117: 156–62.

15.

van der Woude

Winter

Aalbers

. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate bronchoconstriction during high dose treatment with long acting β₂ agonists. Thorax 2001; 56: 529–35.

16.

Jones

Cowan

Flannery

Hancox

Herbison

Taylor

. Reversing acute bronchoconstriction in asthma: The effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001; 17: 368–73.

17.

Suissa

Blais

Ernst

. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7: 162–9.

18.

Anderson GP. Interactions between corticosteroids and β-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am J Respir Crit Care Med 2000; 161: S188–96.

19.

Lemanske

Jr Sorkness

Mauger

Lazarus

Boushey

Fahy

. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 2001; 285: 2594–603.

20.

McIvor

Pizzichini

Turner

Hussack

Hargreave

Sears

. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–30.

21.

Tattersfield

Postma

Barnes

Svensson

Bauer

O'Byrne

. Exacerbations of asthma: A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160: 594–9.

22.

Lazarus

Boushey

Fahy

Chinchilli

Lemanske

Jr Sorkness

. Long-acting β₂ agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001; 285: 2583–93.

23.

Simons

FER

. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337: 1659–65.

24.

Verberne

Frost

Roorda

van der Laag

Kerrebijn

. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156: 688–95.

25.

Waldeck

. Enantiomers of bronchodilating β₂-adrenoceptor agonists: Is there a cause for concern? J Allergy Clin Immunol 1999; 103: 742–8.

26.

Berger

. Levalbuterol: Pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003; 90: 583–92.

27.

Perrin-Fayolle

. Salbutamol in the treatment of asthma (letter). Lancet 1995; 346: 1101.

28.

Cockcroft

Swystun

. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997; 52: 845–8.

29.

Cockcroft

Davis

Swystun

Marciniuk

JDD

. Tolerance to the bronchoprotective effect of β₂ agonists: Comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999; 103: 1049–53.

30.

Nelson

Bensch

Pleskow

DiSantostefano

DeGraw

Reasner

. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102: 943–52.

31.

Jenne

. The debate on S-enantiomers of β-agonists: Tempest in a teapot or gathering storm. J Allergy Clin Immunol 1998; 102: 893–5.

32.

Lotvall

Palmqvist

Arvidsson

Maloney

Ventresca

Ward

. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108: 726–31.

33.

Small

McGraw

Liggett

. Pharmacology and physiology of adrenergic receptor polymorphisms. Ann Rev Pharmacol Toxicol 2003; 43: 381–411.

34.

Turki

Pak

Green

Martin

Liggett

. Genetic polymorphisms of the β₂-adrenergic receptor in nocturnal and nonnocturnal asthma: Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95: 1635–41.

35.

Hall

Wheatley

Wilding

Liggett

. Association of Glu 27 β₂ adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213–4.

36.

Dewar

Wilkinson

Wheatley

Thomas

Doull

Morton

. The glutamine 27 β₂-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100: 261–5.

37.

Hancox

Sears

Taylor

. Polymorphism of the β₂-adrenoceptor and the response to long-term β₂-agonist therapy in asthma. Eur Respir J 1998; 11: 589–93.

38.

Tan

Hall

Dewar

Dow

Lipworth

. Association between β₂ adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995–9.

39.

Martinez

Graves

Baldini

Solomon

Erickson

. Association between genetic polymorphisms of the beta 2-adrenoceptor and response sponse to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184–8.

40.

Summerhill

Leavitt

Gidley

Parry

Solway

Ober

. β₂ Adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 2000; 162: 599–602.

41.

Xie

Stein

Kim

Xiao

Zhou

. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999; 9: 511–6.

42.

Candy

Samani

Norton

Woodiwiss

Radevski

Wheatley

. Association analysis of beta 2 adrenoceptor polymorphisms with hypertension in a Black African population. J Hypertens 2000; 18: 167–72.

43.

Xie

Stein

Kim

Gainer

Sofowora

Dishy

. Human β₂-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. Clin Pharmacol Ther 2000; 67: 670–5.

44.

Kim

S-Y

H-B

Kim

Y-K

Cho

S-H

Kim

Y-Y

. Association of β₂-adrenoceptor polymorphisms with nocturnal cough among atopic subjects but not with atopy and nonspecific bronchial hyperresponsiveness. J Allergy Clin Immunol 2002; 109: 630–5.

45.

Santillan

Camargo

Ramirez-Rivera

Delgado-Enciso

Rojas-Martinez

Cantu-Diaz

. Association between β₂-adrenoceptor polymorphisms and asthma diagnosis among Mexican adults. J Allergy Clin Immunol 2003; 112: 1095–100.

46.

Reihsaus

Innis

MacIntyre

Liggett

. Mutations in the gene encoding for the β₂-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334–9.

47.

Green

Turki

Innis

Liggett

. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414–9.

48.

Taylor

Hancox

McRae

Cowan

Flannery

McLachlan . The influence of polymorphism at position 16 of the beta 2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma 2000; 37: 691–700.

49.

Lee

DKC

Currie

Hall

Lima

Lipworth

. The arginine-16 β₂ adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2003; 57: 68–75.

50.

Israel

Chinchilli

Ford

Boushey

Cherniak

Craig

. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–12.

51.

Silverman

Kwiatkowski

Sylvia

Lazarus

Drazen

Lange

. Family-based association analysis of β₂-adrenergic receptor polymorphisms in the Childhood Asthma Management Program. J Allergy Clin Immunol 2003; 112: 870–6.

52.

Lima

Thomason

Mohamed

MHN

Eberle

Self

Johnson

. Impact of genetic polymorphisms of the β₂-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519–25.

53.

Lima

Mohamed

Self

Eberle

Johnson

. Importance of β₂-adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. Pulm Pharmacol Ther 2000; 13: 127–34.

54.

Lipworth

Dempsey

Aziz

. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 β₂-adrenoceptor polymorphism. Chest 2000; 118: 321–8.

55.

Lipworth

Hall

Tan

Aziz

Coutie

. Effects of genetic polymorphism on ex vivo and in vivo function of β₂-adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8.

56.

Weir

Mallek

Sandford

Bai

Awadh

Fitzgerald

. β₂-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158: 787–91.

57.

Drysdale

McGraw

Stack

Stephens

Judson

Nandabalan

. Complex promoter and coding region β₂-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97: 10483–8.

58.

Small

Brown

Theiss

Seman

Weiss

Liggett

. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced β₂-adrenergic receptor stimulation. Pharmacogenetics 2003; 13: 535–41.

59.

Drazen

Israel

Boushey

Chinchilli

Fahy

Fish

. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335: 841–7.

60.

van Schayck

Graafsma

Visch

Dompeling

van Weel

van Herwaarden

CLA

. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86: 793–800.

61.

Cheung

Timmers

Zwinderman

Bel

Dijkman

Sterk

. Long-term effects of long-acting β₂-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198–203.

62.

Cloosterman

SGM

Bijl-Hofland

van Herwaarden

CLA

Akkermans

van den Elshout

FJJ

Folgering

HTM

. 99–04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473–82.

63.

FitzGerald

Chapman

Cioppa

Della G

Stubbing

Fairbarn

Till

. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999; 103:427–35.

64.

Mann

Chowdhury

Sullivan

Nicklas

Anthracite

Meyer

. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70–4.

65.

Anderson

Ayres

Sturdy

Bland

Butland

Peckitt

. Bronchodilator treatment and deaths from asthma: Case—control study. BMJ 2005; 330:117. DOI 10.1136/bmj.38316.729907.8F

66.

Kelly

Murphy

. Helping children adhere to asthma treatment regimens. Pediatr Asthma Allergy Immunol 2001; 15:25–9.